As India becomes the new and latest nation witnessing the for weight-loss drugs frenzy, Novo Nordisk’s Wegovy challenges Eli Lilly’s Mounjaro in a high-stakes obesity treatment challenge. While early trial results show Mounjaro as the clear winner but what works for you can be different and personalised.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and content measurement, audience insights and product development. List of Partners (vendors)

Around 220,000 people with "greatest need" are expected to receive Mounjaro, also known as tirzepatide and made by Lilly through the NHS over the next three years